Trial Search Results
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.
Stanford is currently accepting patients for this trial.
Collaborator: VIVUS, Inc.
- Biological: ULTRESA
- Biological: PANCREAZE
- Biological: CREON
- Biological: ZENPEP
- Biological: other non-sponsor pancreatic enzyme replacement therapy
- Biological: PERTZYE
- Other: No pancreatic enzyme replacement therapy
The inclusion criteria for enrollment in the Base Study Population
- Diagnosed with cystic fibrosis,
- Enrolled in the Cystic Fibrosis Patient Registry
- Receiving medical care at a Cystic Fibrosis Foundation-accredited care center
providing data to the Cystic Fibrosis Patient Registry
Ages Eligible for Study
N/A - 99 Years
Genders Eligible for Study